This clinical trial is focused on studying treatments for metastatic colorectal cancer, which is a type of cancer that has spread from the colon or rectum to other parts of the body. The study will explore the safety and effectiveness of different treatment combinations that include a new medication called telisotuzumab adizutecan. This medication will be tested alongside other drugs such as ABBV-400, bevacizumab, folinic acid, panitumumab, oxaliplatin, and fluorouracil. These drugs are administered through an intravenous infusion, which means they are given directly into a vein.

The purpose of the study is to evaluate how well these combinations work compared to standard treatments for metastatic colorectal cancer. The study will also assess the safety and tolerability of these combinations, which means checking for any side effects and how well patients can handle the treatment. Additionally, the study aims to find the best dose of telisotuzumab adizutecan to use in future studies. Participants in the study will receive one of the treatment combinations, and some may receive a placebo. The study will last for a period of up to 13 weeks, during which participants will be closely monitored by healthcare professionals.

Throughout the study, researchers will look at various outcomes, such as how long patients live without the cancer getting worse, how long any positive response to the treatment lasts, and overall survival rates. The study will help determine if these new treatment combinations can offer better outcomes for patients with metastatic colorectal cancer. The results will contribute to understanding the potential benefits and risks of these treatments, ultimately aiming to improve care for individuals with this type of cancer.